Ποια είναι η τιμή για Radiopharm Theranostics Limited (RAD)

Η τιμή για Radiopharm Theranostics Limited (RAD) είναι $0.00775813

Ποια είναι η κεφαλαιοποίηση αγοράς για Radiopharm Theranostics Limited (RAD)

Η κεφαλαιοποίηση αγοράς για Radiopharm Theranostics Limited (RAD) είναι $18.35M

Radiopharm Theranostics Limited (RAD) Τιμή και Κεφαλαιοποίηση Αγοράς

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Η τιμή για RAD	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$2,243.84 $18.35M	NVDA	$5.307T	+28,922,381.21%
$1,924.24 $18.35M	AAPL	$4.551T	+24,802,775.62%
$1,756.64 $18.35M	GOOG	$4.154T	+22,642,447.12%
$1,517.39 $18.35M	MSFT	$3.589T	+19,558,573.31%
$1,182.62 $18.35M	AMZN	$2.797T	+15,243,568.08%

Η τιμή για RAD

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$2,243.84 $18.35M